Welcome to our dedicated page for INSULET SEC filings (Ticker: PODD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insulet Corporation filings document the financial, regulatory, governance, and operating disclosures of a medical device company built around the Omnipod tubeless insulin delivery platform. Current reports record quarterly and annual results, Omnipod revenue categories, U.S. and international performance, drug delivery revenue, and related financial-condition disclosures.
Insulet’s SEC filings also cover Regulation FD updates on product-quality and medical device correction matters, material supply agreements, stock repurchase authorizations, executive severance arrangements, auditor changes, and proxy governance. Its definitive proxy materials describe board oversight, executive compensation, leadership structure, and other shareholder-voting matters tied to the company’s public-company governance.
Insulet Corporation insider report: Prem Singh, SVP, Global Operations, reported multiple equity transactions dated 08/07/2025 involving common stock and stock options of Insulet (PODD). The Form 4 shows two acquisitions of common stock for 585 shares at $264.69 and 758 shares at $276.36, and a disposition of 1,343 shares sold at $320. The filing states these transactions were effected under an existing Rule 10b5-1 trading plan. The report also discloses annual non-qualified stock option awards: 585 options at a $264.69 exercise price (expiring 02/28/2032) and 758 options at a $276.36 exercise price (expiring 02/28/2033), each vesting in substantially equal installments over four years. The document lists line-by-line beneficial ownership figures corresponding to each transaction.